SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies.
Saved in:
| Title: | SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies. |
|---|---|
| Authors: | Collier DA; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK., De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Ferreira IATM; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Meng B; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Datir R; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK., Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA., Kemp S SA; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK., Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Fregni CS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA., Bowen J; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA., Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Snell G; Vir Biotechnology, San Francisco, CA 94158, USA., Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Pellanda AF; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland., Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland., Riva A; Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy., Elmer A; NIHR Cambridge Clinical Research Facility, Cambridge, UK., Kingston N; NIHR Bioresource, Cambridge, UK., Graves B; NIHR Bioresource, Cambridge, UK., McCoy LE; Division of Infection and Immunity, University College London, London, UK., Smith KG; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Bradley JR; Department of Medicine, University of Cambridge, Cambridge, UK.; NIHR Bioresource, Cambridge, UK., Temperton N; University of Kent, Canturbury, UK., Ceron-Gutierrez L L; Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK., Barcenas-Morales G; Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK.; Laboratorio de Inmunologia, S-Cuautitlán, UNAM, Mexico., Harvey W; Institute of Biodiversity, University of Glasgow, Glasgow, UK., Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA., Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Doffinger R; Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK., Wills M; Department of Medicine, University of Cambridge, Cambridge, UK., Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA., Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; University of KwaZulu Natal, Durban, South Africa.; Africa Health Research Institute, Durban, South Africa.; Department of Infectious Diseases, Cambridge University Hospitals NHS Trust, Cambridge UK. |
| Corporate Authors: | CITIID-NIHR BioResource COVID-19 Collaboration, COVID-19 Genomics UK (COG-UK) consortium |
| Source: | MedRxiv : the preprint server for health sciences [medRxiv] 2021 Feb 15. Date of Electronic Publication: 2021 Feb 15. |
| Publication Type: | Preprint; Journal Article |
| Journal Info: | Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
